Research on the price of ensidipine and the current situation of medical insurance

Ensidipine (IDHIFA, Enasidenib), as a targeted therapy drug specially designed for patients with acute myeloid leukemia (AML), has demonstrated its unique therapeutic value, especially for patients carrying isocitrate dehydrogenase 2 (IDH2) gene mutations. This small molecule drug is administered orally and can highly selectively bind to the active site of the mutated IDH2 enzyme and exert a therapeutic effect by inhibiting its catalytic activity.

As a small molecule inhibitor ofIDH2, ensidipine has a significant inhibitory effect on mutant IDH2 variants (such as R140Q, R172S and R172K) in in vitro experiments, and the required concentration is much lower than that of the wild-type enzyme. In an IDH2 mutant AML mouse xenograft model, ensidipine effectively reduced 2-hydroxyglutarate (2-HG) levels and induced myeloid differentiation in vitro and in vivo. For AML patients with IDH2 mutations, ensidipine can also reduce 2-HG levels in the blood, reduce the number of blast cells, and increase the percentage of mature bone marrow cells.

However, for domestic patients, ensidipine is not currently available in the country and therefore cannot enjoy the medical insurance reimbursement policy. This means that patients who need this drug have to seek overseas purchase channels or consult professional overseas medical consulting companies. It is understood that generic drugs of ensidipine have been sold overseas, such as the versions produced by Bangladesh's Ziska Pharmaceutical and Laos' Lucius Pharmaceutical, and the price is about more than a box (containing 30 tablets).

Although ensidipine provides new treatment hope forAML patients with IDH2 mutations, and its unique targeting and significant clinical effects have attracted much attention, patients still need to pay close attention to their own responses during use to ensure the safety and effectiveness of the treatment. At the same time, patients also need to pay attention to the price and access to drugs in order to obtain the latest information in a timely manner.

In summary, ensidipine, as an innovative targeted therapy, brings new treatment options to AML patients with IDH2 mutations. However, its price and medical insurance status are still issues that patients and doctors need to face together. It is hoped that more policies and measures will be introduced in the future to reduce the financial burden on patients and allow more patients to benefit from this innovative drug.